ClinicalTrials.gg

Program

lonapegsomatropin

Also written as “Lonapegsomatropin”, “Dual therapy with navepegritide and lonapegsomatropin” and “Lonapegsomatropin [SKYTROFA®]”.

Its studies are mostly in Dwarfism, Pituitary · Turner Syndrome · Achondroplasia, led by 3 companies.

Furthest: phase 3, since Oct 29, 20206 company-led studies, 3 open or runningNext primary completion: Feb 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ascendis Pharma Endocrinology Division31 open or runningphase 3since Oct 29, 2020Oct 29, 2020none ahead
Ascendis Pharma22 open or runningphase 3since Oct 14, 2025Oct 14, 2025Feb 2028phase 3 · NCT07221851
Visen Pharmaceuticals (Shanghai)10 open or runningphase 3since Mar 26, 2020Mar 26, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 26, 2020First study: phase 3 study in Dwarfism, PituitaryNew to Visen Pharmaceuticals (Shanghai)Visen Pharmaceuticals (Shanghai) · NCT04326374 · 150 enrolled · China
  2. Oct 29, 2020Ascendis Pharma Endocrinology Division’s first study: phase 3 study in Dwarfism, PituitaryNew to Ascendis Pharma Endocrinology DivisionAscendis Pharma Endocrinology Division · NCT04615273 · 264 enrolled · United States, Armenia, Australia and more
  3. Sep 24, 2021Phase 3 study in Dwarfism, PituitaryAscendis Pharma Endocrinology Division · NCT05171855 · 220 enrolled · United States, Armenia, Australia and more
  4. Jan 10, 2023Phase 2 study in Turner SyndromeAscendis Pharma Endocrinology Division · NCT05690386 · 48 enrolled · United States
  5. Oct 14, 2025Ascendis Pharma’s first study: phase 3 study in Turner SyndromeNew to Ascendis PharmaAscendis Pharma · NCT07221851 · 186 planned · United States, France, Germany and more
  6. Oct 30, 2026Phase 3 study in AchondroplasiaAscendis Pharma · NCT07924059 · 144 planned

Ahead

  1. Feb 2028Primary completion: phase 3 study in Turner SyndromeAscendis Pharma · NCT07221851
  2. Sep 2028Primary completion: phase 3 study in AchondroplasiaAscendis Pharma · NCT07924059

TargetBeta

GHR →read by rule
“Growth hormone receptor agonist”ChEMBL 37, by rule

Other programs on GHR

ProgramCompanyFurthest phaseStudies
Human Growth HormoneruleNovo Nordiskphase 4118

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07924059Achondroplasia3Not yet recruitingAscendis PharmaSep 2028144
NCT07221851Turner Syndrome · United States, France, Germany and more3RecruitingAscendis PharmaFeb 2028186
NCT05690386Turner Syndrome · United States2Active, not recruitingAscendis Pharma Endocrinology DivisionOct 18, 202448
NCT05171855Dwarfism, Pituitary · United States, Armenia, Australia and more3CompletedAscendis Pharma Endocrinology DivisionDec 23, 2024220
NCT04615273Dwarfism, Pituitary · United States, Armenia, Australia and more3CompletedAscendis Pharma Endocrinology DivisionNov 2, 2023264
NCT04326374Dwarfism, Pituitary · China3UNKNOWNVisen Pharmaceuticals (Shanghai)Apr 2022150

How it is read

Names in the registry

  • “Lonapegsomatropin”, 3 entries
  • “Dual therapy with navepegritide and lonapegsomatropin”, 1 entry
  • “Lonapegsomatropin [SKYTROFA®]”, 1 entry
  • “TransCon hGH”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.